Abstract
9-β-D-Arabinofuranosyladenine was given to two patients by relatively rapid (½, 2 hr) intravenous infusion, to two patients as a continuous intravenous drip over 24 hr, and to two patients as an intramuscular suspension. Blood plasma levels and urinary excretion of ara-A1 and the chief metabolic product. 9-β-D-arabinofuranosylhypoxanthine, were measured at intervals up to 24 hr. Rapid intravenous infusions resulted in 88 and 97% recoveries in urine by 24 hr, as ara-H and ara-A. Urinary excretion after administration as a continuous intravenous drip was 33 and 41%, respectively, in the first 24 hr. The two patients receiving intramuscular injection excreted only 1.7 and 7.1% of the dose, respectively, in 24 hr. The latter finding would indicate poor absorption of an intramuscular dose.
Footnotes
- Received May 29, 1973.
- Copyright © 1973 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|